Similarly, results of a recent study showed that, in the osteosarcoma model, co-treatment with LCL161 and doxorubicin is particularly effective, impeding primary tumor growth and delaying or preventing metastasis; however, it only efficiently kills osteosarcoma cells when TNFα is supplied in vitro [134]. Here, TNF is linked to osteosarcoma.